Publications by authors named "Terron Alberto"

Claim this Profile
I
Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: Substudy of the BIC-NOW clinical trial.
Sergio Sequera-Arquelladas, María J Vivancos, David Vinuesa, Antonio Collado, Ignacio De Los Santos, Alberto Terron, Alberto Romero

PLoS One· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial.
Carmen Hidalgo-Tenorio, Sergio Sequera, María Jesus Vivancos, David Vinuesa, Antonio Collado, Alberto Terron, Alberto Romero

Int J Antimicrob Agents· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).
Carmen Hidalgo-Tenorio, Juan Pasquau, David Vinuesa, Sergio Ferra, Alberto Terrón

Viruses· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial.
Ignacio Pérez-Valero, Juan Pasquau, Rafael Rubio, Antonio Rivero, José Santos, Alberto Terrón

J Antimicrob Chemother· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice.
Maria Saumoy, Josep M Llibre, Alberto Terrón, Hernando Knobel, José Ramón Arribas

AIDS Res Hum Retroviruses· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CNS safety at 48-week of switching to ATV/r plus 3TC or two nucleos(t)ides in HIV-suppressed patients on stable ART: the SALT neurocognitive sub-study.
Ignacio Pérez Valero, Juan Pasquau, Rafael Rubio, Antonio Ribero, Jose Santos, Alberto Terron

J Int AIDS Soc· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monotherapy with darunavir/ritonavir is effective and safe in clinical practice.
Juan Pasquau, Luis López-Cortés, Maria Isabel Mayorga, Pompeyo Viciana, María Del Mar Arenas, Alberto Terrón

J Int AIDS Soc· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Pablo Labarga, Pablo Barreiro, Alfredo da Silva, Josep María Guardiola, Rafael Rubio, Alberto Terrón

J Infect Dis· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort.
Vicente Estrada, Paloma Geijo, Manuel Fuentes-Ferrer, María Luisa García Alcalde, María Rodrigo, Alberto Terrón

BMC Womens Health· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bacterial translocation in HIV-infected patients with HCV cirrhosis: implication in hemodynamic alterations and mortality.
Montserrat Montes de Oca Arjona, Mercedes Marquez, Maria Jose Soto, Claudio Rodriguez-Ramos, Alberto Terron

J Acquir Immune Defic Syndr· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and outcome of HIV infection in gypsies in the Spanish VACH Cohort.
Ramón Teira, Ignacio Suárez-Lozano, Fernando Lozano, Pompeyo Viciana, Pere Domingo, Alberto Terrón

Enferm Infecc Microbiol Clin· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study.
Luis F López-Cortés, Pompeyo Viciana, Rosa Ruiz-Valderas, Juan Pasquau, Josefa Ruiz, Alberto Terrón

AIDS Res Ther· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort.
Domingo Pere, Suarez-Lozano Ignacio, Teira Ramón, Lozano Fernando, Terrón Alberto

Open AIDS J· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.
Alicia Gutiérrez-Valencia, Pompeyo Viciana, Rosario Palacios, Rosa Ruiz-Valderas, Fernando Lozano, Alberto Terrón

Ann Intern Med· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
Manuel Crespo, Esteban Ribera, Ignacio Suárez-Lozano, Pere Domingo, Enric Pedrol, Alberto Terrón

J Antimicrob Chemother· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.
Pere Domingo, Ignacio Suárez-Lozano, Ferran Torres, Ramón Teira, José Lopez-Aldeguer, Alberto Terrón

J Antimicrob Chemother· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minor emtricitabine intolerance in treatment-stable patients switched from tenofovir/lamivudine to a fixed-dose combination of tenofovir/emtricitabine (Truvada).
Rosario Palacios, Alberto Terrón, Ana Hidalgo, Antonio Rivero, Jesús Santos

J Antimicrob Chemother· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natural history of compensated and decompensated HCV-related cirrhosis in HIV-infected patients: a prospective multicentre study.
José A Girón-González, Francisco Brun, Alberto Terrón, Antonio Vergara, Ana Arizcorreta

Antivir Ther· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C.
José A Mira, Juan Macías, José A Girón-González, Dolores Merino, Mercedes González-Serrano, Alberto Terrón

J Antimicrob Chemother· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Changing trends in HIV epidemics: recent diagnoses in the Spanish VACH cohort (2000-2002)].
Ramón Teira, Ignacio Suárez-Lozano, Pepa Muñoz, Pompeyo Viciana, Fernando Lozano, Alberto Terrón

Enferm Infecc Microbiol Clin· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment.
José A Mira, Fernando Lozano, Jesús Santos, Emilia Ramayo, Alberto Terrón

Antivir Ther· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis